then centrifuged to collect the supernatant. The protein concentration was measured with a BCA protein Assay kit (CWBIO, Beijing, China). The samples were mixed with 5X SDS loading buffer.
Approximately 100 μg of each protein sample was used for detection. The proteins were separated by SDS-PAGE and then electroblotted onto polyvinylidene difluoride membranes (Amersham
Biosciences/GE Healthcare Little Chalfont, UK). The membranes were blocked in PBS containing 5% non-fat milk and 0.1% Tween 20 and incubated with primary antibodies at room temperature for 2
h or 4°C overnight, followed by incubation with secondary antibodies at room temperature for 3 h. The results were acquired by exposure to x-ray films after treatment with a mixture of equal
volumes of Luminol/Enhancer Solution and Stable Peroxide Solution (Thermo Scientific, Waltham, MA, USA). β-Actin was used as a control. The primary antibodies used were as follows:
anti-HSD3B1 and anti-HSD11B1 (Abcam, Cambridge, UK, 1:1000), anti-CYP17A1 (Santa Cruz Biotechnology, Dallas, TX, USA, 1:1000) and anti-β‑actin (Abcam, 1:1000). The goat anti-rabbit secondary
antibodies (Abcam) were used at a dilution of 1:5000.